Author

Toshifumi Hibi 1

1 Kitasato University Kitasato Institute Hospital, Tokyo, Japan

A PHASE 3 STUDY OF VEDOLIZUMAB IN JAPANESE PATIENTS WITH ULCERATIVE COLITIS: EFFECTS ON TIME TO DISEASE WORSENING AND TREATMENT FAILURE

Satoshi Motoya, Kenji Watanabe, Haruhiko Ogata, Takanori Kanai, Toshiyuki Matsui, Yasuo Suzuki, Mitsuhiro Shikamura, Kenkichi Sugiura, Kazunori Oda, Tetsuharu Hori, Takahiro Araki, Mamoru Watanabe, Toshifumi Hibi

EFFICACY, SAFETY, AND DEMOGRAPHICS FACTOR OF ORAL TACROLIMUS THERAPY IN 666 JAPANESE PATIENTS WITH REFRACTORY ULCERATIVE COLITIS

Haruhiko Ogata, Takayuki Yamamoto, Reiko Kunisaki, Kota Ishida, Toshifumi Hibi

ADALIMUMAB ACHIEVES COMPLETE REMISSION AT 52 WEEKS IN JAPANESE PATIENTS WITH INTESTINAL BEHÇET'S DISEASE

Fumihito Hirai, Satoshi Tanida, Nagamu Inoue, Makoto Naganuma, Anne Camez, Bidan Huang, Vipin Arora, Morio Ozawa, Toshifumi Hibi, Roopal B Thakkar

SAFETY AND EFFICACY OF HELICOBACTER PYLORI ERADICATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Shinichiro Shinzaki, Toshimitsu Fujii, Shigeki Bamba, Taku Kobayashi, Hiroki Tanaka, Takuya Yoshino, Akihiro Yamada, N. Kamata, Toshifumi Hibi

INDIGO NATURALIS IS EFFECTIVE FOR INDUCING CLINICAL REMISSION AND MUCOSAL HEALING IN PATIENTS WITH ULCERATIVE COLITIS (INDIGO STUDY)

Makoto Naganuma, Shinya Sugimoto, Keiichi Mitsuyama, Taku Kobayashi, Naoki Yoshimura, Katsuyoshi Matsuoka, Tadakazu Hisamatsu, Kenji Watanabe, Takayuki Abe, Yasuo Suzuki, Toshifumi Hibi, Takanori Kanai

Impact of Mirikizumab Treatment on Inflammatory Bowel Disease Questionnaire Scores in Patients with Moderate to Severely Active Crohn's Disease

Bruce E. Sands, William Sandborn, Laurent Peyrin-Biroulet, Peter Higgins, Fumihito Hirai, Vipul Jairath, Ruth Belin, Yan Dong, Elisa Gomez Valderas, Debra Miller, MaryAnn Morgan-Cox, April Naegeli, Paul Pollack, Jay Tuttle, Toshifumi Hibi

SUBMUCOSAL INJECTION OF THE RNA OLIGONUCLEOTIDE STNM01 IN ACTIVE ULCERATIVE COLITIS INDUCES MUCOSAL HEALING AND REVERSES TISSUE REMODELING

Raja Atreya, Tanja Kühbacher, Maximilian J. Waldner, Simon Hirschmann, Oliver Drvarov, Raed Abu Hashem, Christian Maaser, Torsten Kucharzik, Johanna Dinter, Jessica Mertens, Christoph Schramm, Babett Holler, Joachim Mössner, Kenji Suzuki, Naoyuki Yokoyama, Shuji Terai, Hiroyuki Yoneyama, Hitoshi Asakura, Toshifumi Hibi,

TOFACITINIB HAS INDUCTION EFFICACY IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS, REGARDLESS OF PRIOR TNF INHIBITOR THERAPY

Geert R. D'Haens, Bruce E. Sands, William Sandborn, Toshifumi Hibi, Chinyu Su, Wojciech Niezychowski, Subrata Ghosh, Haiying Zhang, Dahong Yu, Deborah A. Woodworth, Paul Healey, Amy Marren, Julian Panés

USEFULNESS OF COMBINATION THERAPY WITH ADALIMUMAB AND IMMUNOMODULATORS IN PATIENTS WITH CROHN’S DISEASE: A LARGE, MULTI-CENTRE COHORT STUDY

Hiroki Tanaka, N. Kamata, Akihiro Yamada, Toshimitsu Fujii, Katsuya Endo, Takuya Yoshino, Shigeki Bamba, Takeshi Sugaya, Takaaki Kawaguchi, Manabu Ishii, Shinichiro Shinzaki, Yosuke Toya, Yuka Yanai, Yoko Yokoyama, Junji Umeno, Toshihiko Okada, Taku Kobayashi, Masanori Nojima, Toshifumi Hibi

Efficacy and Safety of Mirikizumab (LY3074828) in a Phase 2 Study of Patients with Crohn's Disease

Bruce E. Sands, William Sandborn, Laurent Peyrin-Biroulet, Peter Higgins, Fumihito Hirai, Ruth Belin, Elisa Gomez Valderas, Debra Miller, MaryAnn Morgan-Cox, April Naegeli, Paul Pollack, Jay Tuttle, Toshifumi Hibi

Item 1 - 10 / 10
1
We use cookies in order to provide you with a better browsing experience. This includes third-party cookies for traffic analyzation purposes. See here for more information.
OK